NFKB1 and nasopharyngeal carcinoma: In vivo and in vitro data demonstrate that S10014 inhibits NPC cellular motility via the NF-κB signaling pathway; moreover, it has been discovered that overexpression of S100A14 lowers the risk of NPC resistance to cisplatin [192,196,197,198,199,200].